Rubella is an infectious disease caused by rubella virus, a virus of the Matonaviridae family. It is often a relatively mild illness in children and adults, commonly producing a fine maculopapular rash, low-grade fever and lymph-node enlargement, particularly behind the ears and at the back of the head. Despite the usually mild nature of postnatal infection, rubella is medically important because infection during pregnancy can cause congenital rubella syndrome and severe fetal injury. This distinction makes rubella prevention particularly important in reproductive and public health.
Rubella spreads primarily through respiratory droplets and aerosols generated by infected people. The incubation period is commonly around two to three weeks. Individuals can transmit the virus before the rash develops and for a period afterwards, and some infections are asymptomatic, making transmission difficult to recognise through symptoms alone. The rash generally begins on the face and spreads to the trunk and limbs, often resolving within a few days. Postauricular and occipital lymphadenopathy is a useful clinical clue, although no single clinical feature definitively establishes rubella infection.
Rubella infection acquired after birth is usually mild but can occasionally cause arthralgia or arthritis, particularly in adult women. More serious complications are uncommon, but encephalitis and thrombocytopenic complications can occur rarely. The major concern is congenital infection. If a susceptible pregnant person acquires rubella, particularly early in pregnancy, the virus can cross the placenta and disrupt fetal development. The resulting congenital rubella syndrome can include sensorineural hearing loss, eye abnormalities such as cataracts, congenital heart disease, developmental impairment and other organ damage.
Congenital rubella syndrome reflects the developmental consequences of fetal viral infection rather than simply a severe form of the mother's rash illness. The risk of major fetal effects is particularly high when infection occurs during the early stages of pregnancy. A pregnant person may have minimal or no symptoms while fetal infection is nevertheless occurring, so clinical absence of illness does not exclude risk. This is why prevention through vaccination before pregnancy and appropriate assessment following suspected exposure are central to rubella control.
Laboratory diagnosis is important because rubella can resemble other rash-producing illnesses, and clinical diagnosis alone is unreliable. Serological testing can assess rubella-specific antibodies, while molecular methods may be useful in selected circumstances. Interpretation becomes more complicated in vaccinated people or those with previous infection because antibodies can reflect immunity rather than recent infection. During pregnancy, specialist interpretation of test results and exposure history is important because unnecessary conclusions can cause significant anxiety, whereas failure to identify genuine infection can have serious consequences.
Prevention is based mainly on vaccination with rubella-containing vaccine, usually delivered through the combined MMR vaccine. The vaccine uses a live attenuated rubella virus and provides strong protection. Because the vaccine is not routinely given during pregnancy, ensuring immunity before pregnancy is particularly important. High vaccination coverage protects not only vaccinated individuals but also reduces circulation of the virus and thereby reduces opportunities for pregnant people to encounter infection. Susceptible people planning pregnancy can therefore benefit from checking vaccination status in advance according to national guidance.
Rubella should not be confused with measles, despite the historical expression German measles. The two infections are caused by different viruses and have different public-health implications. Rubella generally produces a milder illness than measles, but its potential fetal consequences make it particularly important in pregnancy. Another misconception is that a mild maternal illness means there is little fetal risk; congenital infection can occur despite limited maternal symptoms. Antibiotics do not treat rubella because it is viral, and vaccination prevents infection rather than treating established fetal infection.
Global control of rubella depends on sustained vaccination coverage, laboratory-supported surveillance and identification of susceptible populations. Successful vaccination programmes have greatly reduced congenital rubella syndrome in many settings. However, gaps in immunisation can permit outbreaks and reintroduction through travel. Rubella control is therefore closely linked to maternal and child health, immunisation policy and surveillance systems. The central epidemiological objective is to prevent infection among people who could become pregnant and thereby interrupt the pathway from community transmission to congenital disease.
